Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

DCDavid G. CoffeySFStephanie FernandesCDC. Caballero Díaz

Discussion

Loading...

Member takes

Overview

Integrated sequencing shows high concordance of genomic mutations in plasma of multiple myeloma patients, highlighting liquid biopsy's potential for molecular characterization.

Key Points

  • Integrated sequencing detected significant mutations in cell-free DNA from plasma in multiple myeloma patients, showing high concordance with bone marrow results.
  • The median number of coding mutations was 7 detected in bone marrow, while circulating plasma samples reflected up to 85.7% concordance.
  • Next-generation sequencing methods were used to assess both plasma-derived cell-free DNA and RNA, enabling comprehensive molecular profiling of tumors.
  • Liquid biopsy offers a minimally invasive approach for monitoring disease evolution and treatment response in multiple myeloma patients.

Cite This Study

Coffey et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbf4https://doi.org/10.1182/blood-2025-7483
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma2025
  2. 2Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients2025
  3. 3Targeted deep sequencing of myeloma in a multi-institutional clinical workflow2025
  4. 4Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study2025 · 1 citations
  5. 5Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma2025